Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEquity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income - MinorityNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Gsk (GLAXF) EBITDA (2016 - 2025)

Historic EBITDA for Gsk (GLAXF) over the last 17 years, with Q3 2025 value amounting to $3.5 billion.

  • Gsk's EBITDA rose 132448.73% to $3.5 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $13.0 billion, marking a year-over-year increase of 3763.55%. This contributed to the annual value of $5.1 billion for FY2024, which is 3873.42% down from last year.
  • As of Q3 2025, Gsk's EBITDA stood at $3.5 billion, which was up 132448.73% from $2.7 billion recorded in Q2 2025.
  • Over the past 5 years, Gsk's EBITDA peaked at $5.9 billion during Q4 2021, and registered a low of $245.6 million during Q3 2024.
  • In the last 5 years, Gsk's EBITDA had a median value of $2.5 billion in 2023 and averaged $2.7 billion.
  • Its EBITDA has fluctuated over the past 5 years, first tumbled by 9005.3% in 2024, then surged by 132448.73% in 2025.
  • Gsk's EBITDA (Quarter) stood at $5.9 billion in 2021, then plummeted by 32.62% to $4.0 billion in 2022, then surged by 32.44% to $5.2 billion in 2023, then decreased by 23.21% to $4.0 billion in 2024, then decreased by 13.09% to $3.5 billion in 2025.
  • Its EBITDA stands at $3.5 billion for Q3 2025, versus $2.7 billion for Q2 2025 and $2.8 billion for Q1 2025.